Ameriprise Financial Inc. reduced its position in shares of Hill-Rom Holdings Inc. (NYSE:HRC) by 31.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,486 shares of the medical technology company’s stock after selling 65,315 shares during the period. Ameriprise Financial Inc. owned approximately 0.22% of Hill-Rom Holdings worth $7,290,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. LSV Asset Management purchased a new position in Hill-Rom Holdings during the second quarter worth $730,000. Airain ltd increased its position in Hill-Rom Holdings by 26.6% in the second quarter. Airain ltd now owns 32,748 shares of the medical technology company’s stock worth $1,652,000 after buying an additional 6,880 shares in the last quarter. First Trust Advisors LP increased its position in Hill-Rom Holdings by 38.5% in the second quarter. First Trust Advisors LP now owns 385,219 shares of the medical technology company’s stock worth $19,434,000 after buying an additional 107,020 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Hill-Rom Holdings during the second quarter worth $357,000. Finally, State Board of Administration of Florida Retirement System increased its position in Hill-Rom Holdings by 12.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 86,383 shares of the medical technology company’s stock worth $4,358,000 after buying an additional 9,832 shares in the last quarter. 83.11% of the stock is currently owned by institutional investors.
Shares of Hill-Rom Holdings Inc. (NYSE:HRC) traded up 0.48% during mid-day trading on Friday, reaching $62.21. The company’s stock had a trading volume of 591,726 shares. The firm has a market cap of $4.07 billion, a P/E ratio of 64.07 and a beta of 1.14. Hill-Rom Holdings Inc. has a 12-month low of $42.99 and a 12-month high of $62.43. The firm’s 50-day moving average price is $59.85 and its 200 day moving average price is $53.46.
Hill-Rom Holdings (NYSE:HRC) last announced its earnings results on Thursday, August 4th. The medical technology company reported $0.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.05. Hill-Rom Holdings had a return on equity of 16.62% and a net margin of 2.47%. The firm had revenue of $655.40 million for the quarter, compared to the consensus estimate of $647.75 million. During the same period in the previous year, the business earned $0.62 EPS. The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. On average, analysts expect that Hill-Rom Holdings Inc. will post $3.33 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 30th. Investors of record on Friday, September 16th were paid a dividend of $0.17 per share. The ex-dividend date was Wednesday, September 14th. This represents a $0.68 annualized dividend and a yield of 1.09%. Hill-Rom Holdings’s dividend payout ratio (DPR) is 73.91%.
A number of research firms have weighed in on HRC. Zacks Investment Research downgraded Hill-Rom Holdings from a “buy” rating to a “hold” rating in a report on Wednesday. KeyCorp restated a “buy” rating and issued a $59.00 price target on shares of Hill-Rom Holdings in a research report on Thursday, June 23rd. Finally, Morgan Stanley upgraded Hill-Rom Holdings from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $54.00 to $62.00 in a research report on Thursday, June 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $62.20.
About Hill-Rom Holdings
Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.